Tech Company Financing Transactions
Epigenic Therapeutics Funding Round
Epigenic Therapeutics, operating out of Shanghai, scored $20 million from FountainBridge Capital, Kingray Capital and Morningside Group.
Transaction Overview
Company Name
Announced On
8/8/2022
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to validate advances of its proprietary epigenetic editing in non-human primates, expand expertise and capabilities, and sponsor early-stage clinical investigations.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Floor 5&6, Unit 1, Building 4, 160 Basheng Road, Pilot Free
Shanghai, Undisclosed
CN
Shanghai, Undisclosed
CN
Phone
Undisclosed
Website
Email Address
Overview
Epigenic Therapeutics is a frontier biotechnology company dedicated to developing next generation gene editing thera utilizing regulation of epigenetic genome for a variety of diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bob Zhang
Browse more venture capital transactions:
Prev: 8/8/2022: Utility Global venture capital transaction
Next: 8/8/2022: Yoodli venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document funding rounds that are announced publicly. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs